Safety and efficacy of emicizumab and other novel agents in newborns and infants

Glenn F Pierce¹, Daniel P Hart^{1

2

3}, Radoslaw Kaczmarek^{1

4

5}; Committee on Coagulation Products Safety Supply, Access (CPSSA) of the World Federation of Hemophilia (WFH)

Affiliations

¹ Coagulation Products Safety Supply and Access Committee of the World Federation of Hemophilia, Montreal, Québec, Canada.
² Barts and The London School of Medicine and Dentistry, Blizard Institute, QMUL, London, UK.
³ The Royal London Hospital Haemophilia Centre, Barts Health NHS Trust, London, UK.
⁴ Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA.
⁵ Laboratory of Glycobiology, Polish Academy of Sciences, Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland.

Glenn F Pierce et al. Haemophilia. 2019 Sep.

. 2019 Sep;25(5):e334-e335.

doi: 10.1111/hae.13822. Epub 2019 Jul 30.

Glenn F Pierce¹, Daniel P Hart^{1

2

3}, Radoslaw Kaczmarek^{1

4

5}; Committee on Coagulation Products Safety Supply, Access (CPSSA) of the World Federation of Hemophilia (WFH)

¹ Coagulation Products Safety Supply and Access Committee of the World Federation of Hemophilia, Montreal, Québec, Canada.
² Barts and The London School of Medicine and Dentistry, Blizard Institute, QMUL, London, UK.
³ The Royal London Hospital Haemophilia Centre, Barts Health NHS Trust, London, UK.
⁴ Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA.
⁵ Laboratory of Glycobiology, Polish Academy of Sciences, Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland.

No abstract available

Publication types